Stat – Aug. 29
But Dr. Robert Gatenby was especially aware of the stakes. An oncologist at Moffitt Cancer Center in Tampa, Fla., he has spent years studying how tumor cells respond to chemotherapy, especially in patients whose cancer has metastasized well beyond the original tumor, as when malignant prostate cells invade bones like gang members expanding their turf.
North Coast Journal of Politics, People and Art – Aug. 29
“It may be tough to convince patients, even those with an incurable disease, that the best approach is not to kill as many cancer cells as possible but as few as necessary." — James DeGregori and Robert Gatenby, Scientific American, August, 2019
Infectious Diseases Society of America – Aug. 29
Aliyah Baluch, MD, MSc, Moffitt Cancer Center, Tampa, FL
Citrus County Chronicle – Aug. 27
Other area heath care organizations that also use the app include Advent Health hospitals, Moffitt Cancer Center, University of South Florida Care, Tampa General Hospital, Heart of Florida Regional Medical Center and its physicians groups, Shands satellite facilities and Tenet Health.
Globe Newswire – Aug. 27
The company has started to work with Moffitt Cancer Center, Rhode Island Hospital and the University of Cambridge, and is in collaboration discussions with additional cancer centers around the globe.
OncLive – Aug. 27
Data collection will also take place in these locations: Florida: Moffitt Cancer Center
Health News Digest – Aug. 27
In a new study published in Clinical Cancer Research, Moffitt Cancer Center researchers describe promising results from an early clinical trial that may offer patients who progress after ICI an additional treatment option. Also posted to Scienmag.com and Medical Xpress.
Asbestos.com – Aug. 26
The Moffitt Cancer Center is just one of four institutions hosting the trial. The others include Regions Hospital Cancer Center in St. Paul, Minnesota; Karmanos Cancer Center in Detroit; and the University of Maryland Cancer Center in Baltimore.
Liebertpub.com – Aug. 26
Kristine Donovan, PhD, MBA and colleagues from Moffitt Cancer Center, Tampa, FL coauthored the article entitled “Cannabis Use in Young Adult Cancer Patients.” On urine drug testing for a breakdown product of cannabis, they showed that 30% of young adult cancer patients ages 18 to 39 tested positive.
DotMed – Aug. 26
Researchers at the Moffitt Cancer Center have proposed the development of what they claim would be the first genomically-based model for personalizing radiation oncology treatment for individual patients.
The Global Dispatch – Aug. 26
The Florida Invention Convention is sponsored by USF College of Engineering, the National Academy of Inventors (USF Chapter), Moffitt Cancer Center, the Intellectual Property Law Firm of Saliwanchik, and Lloyd and Eisenschenk.
WFLA – Aug. 25
Dr. Bijal Shah, an associate at the Moffitt Cancer Center’s and clinical director of the acute lymphoblastic leukemia program, says that there is no scientific research to support the efficacy of treatments with cannabis, which Bland-Ball and McAdams were seeking as an alternative to chemotherapy.
Clincalomics – Aug. 23
Researchers at Moffitt Cancer Center have partnered with investigators at the Dana-Farber Cancer Institute and Foundation Medicine to develop what Moffitt said was the largest descriptive genomic analysis to date of patients with Merkel cell carcinoma (MCC).
Please note we cannot guarantee the accuracy or availability of links. The stories belong to the respective publishers, and links may expire. Some news sites require you to register and select a password in order to retrieve articles, but most usually do not charge a fee to retrieve these news stories.